Chemo Free Frontline Regimen Improves Ph Positive ALL EFS
A peer-reviewed randomized Phase 3 GIMEMA ALL2820 trial published online in the New England Journal of Medicine found that frontline ponatinib plus blinatumomab improved 24-month event-free survival versus imatinib plus chemotherapy in adults with…
